Resumen
The majority of high grade serous ovarian carcinoma (HGSOC) patients present with advanced disease, which will relapse and require additional treatment. Although the presence of ascites and/or pleural effusion in relapsed HGSOC is not rare, there is a lack of data in this setting. This population of patients typically presents a very poor prognosis and often there is no response to the treatment. One could ask if giving the ?right therapy to the right patients? would change the course of the disease. The aim of this retrospective, multi-centric and real-life study was to compare the overall survival (OS) of two groups of advanced HGSOC patients, who present with ascites or pleural effusion: responders, i.e., patients that had an imagological response to treatment (complete/partial response/stable disease, RECIST criteria) versus non-responders (no response/progression upon treatment), and to evaluate the predictive value of the standard clinical variables. We concluded that patients who have a tumoral response to first and second line of treatment have a ~3 times longer Progression-free Survival (PFS) or OS. The response to the treatment was irrespective of patient and tumor characteristics, which highlights the need for a sensitivity test to tailor treatments and improve efficacy rates in a personalized manner.